Innovation is essential to promoting human health, agricultural productivity, and ecological sustainability. ITIF’s Center for Life Sciences Innovation conducts research supporting advances in human biotechnology; pharmaceuticals; and health care policy outside the realm of IT.
How Japan Squandered Its Biopharmaceutical Competitiveness: A Cautionary Tale
Stringent drug price controls have significantly hampered the competitive and innovative capacity of Japan’s biopharmaceutical industry in recent decades, serving as a warning for U.S. policymakers considering introducing Medicare Part D drug price controls in 2022.
Testimony to the Senate Finance Committee on “Prescription Drug Price Inflation”
More Publications and Events
October 13, 2022|Presentations
Lessons From Mexico’s Life Sciences Innovation Ecosystem for Indonesia
Stephen Ezell joins the program at HigherHeight 2022, hosted by Pfizer Indonesia and the Indonesian Biotechnology Study Program Association (IPSBI), to discuss what Indonesia can learn from Mexico’s experiences in building up its life sciences innovation ecosystem.
August 9, 2022|Press Releases
Reconciliation Bill Detrimental for U.S. Life Sciences Innovation, Says ITIF
The Inflation Reduction Act of 2022 incorporates unnecessary and unwarranted drug price controls that will harm America’s life-sciences innovation industry and deter biomedical innovation.
August 5, 2022|Blogs
Senate Reconciliation Legislation Fails to Reconcile the Interests of Biomedical Innovation and Drug Price Affordability
The bill fails to recognize three critical realities: 1) that drug prices are, in fact, not a significant driver of raging inflation; 2) that there exist better mechanisms to reform Medicare Part D drug pricing practices; 3) that mandated government price controls do inflict serious harm on nations’ life-sciences innovation systems.
August 1, 2022|Podcasts
Podcast: Life Sciences Innovation Through the Bayh-Dole Act, With Joe Allen
Rob and Jackie sat down with Joe Allen, who served as a professional staffer on the U.S. Senate Judiciary Committee to former Senator Birch Bayh, to discuss the importance of the Bayh-Dole Act and the future of life sciences innovation.
July 8, 2022|Blogs
Senate Democrats’ Drug Price Proposal Would Slow the Pace of New Drug Discovery
Congress should ignore pressure from progressive activists who want to use drug price controls to move to a government-led drug discovery and production system and instead focus on more pragmatic reforms.
June 24, 2022|Blogs
Postmortem on a Pyrrhic Victory for IP Foes at the WTO
The WTO’s approval of a TRIPS waiver for IP related to COVID-19 vaccines is essentially a shotgun blast completely missing the broadside of a barn.
June 17, 2022|Blogs
No, America’s Drug Prices Aren’t Climbing Radically Out of Control
The United States uniquely leads the world in innovating new drugs and getting them to patients first while sustaining a globally competitive industry and over time making drugs affordable by incentivizing competition and creating generic pathways.
June 10, 2022|Blogs
USG Remains Misguided in Endorsing COVID-19 TRIPS IPR Waiver
Instead of conflicting mandates, the Biden administration should articulate a coherent set of policies recognizing that IP represents a fundamental and distinguishing driver of American innovation and technological competitiveness. Support for the TRIPS COVID-19 IPR waiver cannot be consonant with such an agenda.
April 27, 2022|Events
Innovation and IP’s Role in Combatting the Covid-19 Pandemic
ITIF and the Center for Strategic and International Studies hosted two expert panels exploring how innovation and IP have proved to be instrumental in overcoming the COVID pandemic.
March 29, 2022|Events
How Using March-in Rights Would Threaten America’s Research Universities
ITIF hosted a panel discussion with leading experts on innovation policy, technology transfer, and business, who spoke to the practical implications of exercising federal “march-in” rights and why it would be a grave and ill-timed mistake for the U.S. health, competitiveness, and research landscape.